Anxiety disorders are very common illnesses that are reported in approximately one third to one quarter of the entire population during the lifetime. Many anxiety disorders are being reported early in life, they have chronic progress, and cause significant difficulties, interfere in daily life activities and create huge economical expenses. It has been evaluated that 46.6 billion dollars out of 147.8 billion dollars overall mental disorders expenses in US is being spent on anxiety disorders, while in European community those expenses exceed 41 billion Euros. In spite of that, pharmacoeconomical aspects of these illnesses so far drawn much less attention than so called large mental illnesses (schizophrenia, depression), and the reason for that is probably that earlier relatively cheep benzodiazepines were dominantly used in treating anxiety disorders. However, in newer times the anti-depressives became the first choice for anxiety disorders, especially those from the group of selective serotonin reuptake inhibitors (SSRI). The increase of anxiety disorders prevalence and changes in modern pharmacotherapy create promising research conditions for starting the studies in area of pharmacoeconomics in the world, and in our country